1 to 10 of 65 Results
Adobe PDF - 104.8 KB -
MD5: a41f0a491698a4068a5469bc2b8497ba
|
Adobe PDF - 290.5 KB -
MD5: 9f4f9186d4e6bd4d1a751866499a814d
Supplementary Material of the Article "Serum anti-lipid antibodies in patients affected by leprosy in a high-burden municipality in Brazil: a cross-sectional study" |
Adobe PDF - 104.2 KB -
MD5: e6a8e8a2ad3efcffabfc9ae87ee36dfb
|
Adobe PDF - 804.2 KB -
MD5: 007e6476da7bc566fbf31711e017744e
Supplementary Material of the Article "An integrative review on treatment guidelines for complicated urinary tract infections: a synthesis of evidence-based recommendations" |
Adobe PDF - 146.0 KB -
MD5: 0f85670e528961c23ca18b98a4a062e0
|
Adobe PDF - 705.3 KB -
MD5: 35768bea270531ad716eb988bea4578e
Supplementary Material of the Article "Immunomodulatory effects of Triatoma dimidiata feces on Trypanosoma cruzi infection in a murine model" |
Adobe PDF - 138.7 KB -
MD5: c54ac1c0b7afbcf4f7e880ebf13c6137
|
Adobe PDF - 512.9 KB -
MD5: f70f101c6687c3edce368001dc7db183
Supplementary Material of the Article "Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals" |
Nov 18, 2024 -
Supplementary Material of the Article "Innate-immune cell distribution in pediatric HIV patients and uninfected controls"
Adobe PDF - 100.3 KB -
MD5: 7456a9e7a01bfd73705ad203da5d9de4
|
Nov 18, 2024 -
Supplementary Material of the Article "Innate-immune cell distribution in pediatric HIV patients and uninfected controls"
Adobe PDF - 787.5 KB -
MD5: 7d11f8dd9be1dcbbf6163d2176e49c31
Supplementary Material of the Article "Innate-immune cell distribution in pediatric HIV patients and uninfected controls" |